Get the most up-to-date knowledge on the management of Neuroendocrine Tumors and other oncologic pathologies associated with glands and hormones through this very complete TECH’s Endocrine Oncologic Pathology” 

Through scientific and technological advances, medicine is constantly updating the strategies and tools used for the diagnosis and treatment of Endocrine Oncologic Pathologies. An example of these is the emergence of modern genetic tests to identify familial DNA mutations that indicate the possible occurrence of Multiple Endocrine Neoplasia Syndromes. The same applies to the approach to Neuroendocrine Tumors where Peptide Receptor Radionuclide Therapy has become more relevant. The constant renewal of this health field makes it difficult to update specialists, who often demand academic programs that facilitate the assimilation of new concepts and skills. 

Aware of this scenario, TECH has developed a pioneering educational modality that will solve these problems. In this way, the Endocrine Oncologic Pathology in Endocrine Oncologic Pathology combines, like no other degree, all the knowledge that the physician will need to be at the forefront of this area of health care. 

The pedagogical itinerary consists of two distinct parts. The first part dedicates 1,500 hours to the theoretical and online study of the most significant contributions to this health specialty in recent years. In addition to delving into the clinical manifestations recently discovered for some types of tumors, it examines the methodologies to be followed for their correct identification and elimination. For the mastery of all the contents offered by this educational opportunity, TECH also provides Relearning, an innovative learning model of great didactic value. 

In the second phase of this program, there will be a clinical internship to be completed in 3 weeks.This intensive, face-to-face stay will enable the specialist to be exposed to first-rate technological resources for the approach to endocrine tumors. Also in this pedagogical stage, the specialist will apply innovative care protocols on real patients, directly verifying their multidisciplinary support. You will also receive advice from leading experts in the field and the personalized guidance of an assistant tutor. Through all these elements, the graduate will have the best update and will be able to add the most modern procedures in the market to their medical practice.

Throughout 1,500 hours of theoretical study, you will be updated on the steps to follow for the multidisciplinary approach to Multiple Endocrine Neoplasia Syndromes” 

This Hybrid professional master’s degree in Endocrine Oncologic Pathology contains the most complete and up-to-date scientific program on the market. The most important features include: 

• More than 100 clinical cases presented by Endocrine Oncologic Pathology experts 
• The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
• Comprehensive systematized action plans for the main pathologies
• Presentation of practical workshops on procedures diagnosis, and treatment techniques
• An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the course
• Practical clinical guides on approaching different pathologies 
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection 
• Furthermore, you will be able to carry out a clinical internship in one of the best hospital centers 

The 3 weeks of clinical practice integrated to this Hybrid professional master’s degree will give you access to real patients, with various endocrine oncologic pathologies, which you will treat according to the most updated protocols of this specialty” 

In this proposal for a Master's Degree, of a professionalizing nature and hybrid learning modality, the program is aimed at updating professionals who require a high level of qualification in relation to the management of Endocrine Oncologic Pathology. The contents are based on the latest scientific evidence, and oriented in an educational way to integrate theoretical knowledge into practice, and the theoretical-practical elements will facilitate knowledge update and decision-making in patient management. 

Thanks to the multimedia content, developed with the latest educational technology, Medicine professionals will benefit from contextual learning, i.e., a simulated environment that will provide immersive learning programmed to train in real situations. This program is designed around Problem-Based Learning, whereby the professional must try to solve the different professional practice situations that arise throughout the program. For this purpose, the students will be assisted by an innovative interactive video system created by renowned and experienced experts.

During the 100% online study of the first stage of this degree, you will add to your professional practice the most modern strategies for the approach of differentiated thyroid carcinoma tumors” 

By means of this Hybrid professional master’s degree, you will apply novel treatments against Neuroendocrine Tumors such as Radionuclide Therapy with peptide receptor radionuclides through radiopharmaceuticals such as Lutathera” 

The syllabus of this program provides an in-depth theoretical overview of the pathogenesis of all types of tumors of endocrine origin. In particular, it examines those affecting the glands of the Pituitary, Hypothalamus, Thyroid, among others. At the same time, it analyzes in detail the most recently implemented diagnostic methods in Endocrine Oncology. It will also expand the specialist's knowledge about the origin, symptoms and treatments against Multiple Endocrine Neoplasia Syndromes. The study of the academic modules of this very complete syllabus will be supported, at all times, by methodologies of great didactic value such as Relearning. 

Add the most revolutionary concepts and topics of interest in Endocrine Oncology to your theoretical knowledge through multimedia resources such as infographics, videos and interactive summaries” 

Module 1. Hypothalamic-Pituitary Tumor Pathology

1.1. Pituitary Tumors Pathogenesis
1.2. Clinical and Prognostic Classification for Selar Tumors: List Clinical, Radiological, Functional and Anatomical Pathological Elements to Characterize the Prognosis of Selar Lesions

1.2.1. Adenomas

1.2.1.1. Clinical, Functional and Radiological Classification
1.2.1.2. Pathological Anatomy of Pituitary Adenomas

1.2.2. Non-Adenomatous Selar Tumors: Rathke's Pouch (Cysts, Craniopharyngiomas), Meningiomas
1.2.3. Non-Proliferative Lesions: Inflammatory, Hemorrhagic

1.3. Imaging Study for Hypothalamic-Pituitary Tumor Pathology
1.4. Ophthalmologic Evaluation for Hypothalamic-Pituitary Tumor Pathology
1.5. Prolactinoma Differential Diagnosis for Hyperprolactinemia
1.6. Acromegaly
1.7. ACTH-Dependent Cushing's Syndrome: Cushing's Disease
1.8. Non-Functioning Pituitary Adenomas and Gonadotropinomas
1.9. Less Common Pituitary Adenomas

1.9.1. Thyrotropinomas: Adenomas Plurihormonales
1.9.2. Aggressive Pituitary Adenomas

1.10. Other Selar Area Tumors

1.10.1. Rathke's Pouch Cyst and Craniopharyngioma
1.10.2. Meningioma Pituicytoma

1.11. Surgical Treatment for Selar and Parasellar Lesions

1.11.1. Surgical Treatment
1.11.2. Postoperative Hypothalamic-Pituitary Functional Evaluation

1.12. Radiotherapy and Radionuclide Therapy for Selar and Parasellar Lesions

1.12.1. Radiotherapy
1.12.2. Radionuclide Therapy
1.12.3. Long-term Monitoring after Radiotherapy

1.13. Importance of Tumor Committees and Patient Associations

1.13.1. Multidisciplinary Approach
1.13.2. Role of Patient Associations: Association of Patients Affected by Acromegaly

Module 2. Thyroid Nodule Management: Parathyroid Tumors

2.1. Causes of Nodular Thyroid Disease: Thyroid Incidentaloma
2.2. Nodular Thyroid Disease Evaluation: Data Suggesting Malignancy Suspicion

2.2.1. Clinical Data, Personal History, Family History
2.2.2. Exploration Data: Laboratory Data

2.3. Ultrasound in the Evaluation of Nodular Thyroid Disease

2.3.1. Cervical Ultrasound
2.3.2. TI-RADS Classification: ATA Classification

2.4. Thyroid Gammagraphy: Other Imaging Techniques
2.5. Nodular Thyroid Disease Cytological Studies

2.5.1. Fine Needle Aspiration Puncture (FNA) with Ultrasound Monitoring
2.5.2. Bethesda’s Classification

2.6. Hyperthyroidism Caused by Hyperfunctioning Thyroid Nodule: Hyperfunctioning Multinodular Goiter Treatment
2.7. Molecular Markers Use: What to Do with a Bethesda III?
2.8. Nodular Thyroid Disease Surgical Treatment

2.8.1. Indications
2.8.2. Types of Treatment

2.9. Other treatments

2.9.1. Ethanolization
2.9.2. Laser Thermal Ablation
2.9.3. Radiofrequency Thermal Ablation

2.10. Approach to Primary Hyperparathyroidism

2.10.1. Classification
2.10.2. Biochemical Diagnosis
2.10.3. Imaging Tests
2.10.4. Treatment

Module 3. Differentiated Thyroid Carcinoma (DTC)

3.1. Molecular Aspects of Differentiated Thyroid Carcinoma: Clinical Implications
3.2. Pathological Anatomy of Thyroid Carcinoma: Classification
3.3. Follicular Neoplasm with Papillary-Like Changes (FANFIC)
3.4. Papillary Microcarcinoma

3.4.1. Is Only Monitoring Possible?
3.4.2. When to Treat
3.4.3. How to Treat

3.5. Initial Staging 8th Classification Differences with the 7th Classification
3.6. Surgical Treatment

3.6.1. Initial Surgical Treatment
3.6.2. Relapse Treatment

3.7. Radioiodine Treatment

3.7.1. When to Treat
3.7.2. Treatment Dose
3.7.3. Radioiodine Refractoriness

3.8. Follow up Dynamic Risk Staging
3.9. Treatment of Advanced Unresectable DTC
3.10. Importance of Tumor Committees and Patient Associations

3.10.1. Multidisciplinary Approach
3.10.2. Role of Patient Associations: AECAT (Spanish Association of Thyroid Cancer)

Module 4. Medullary Thyroid Carcinoma (MTC): Other Thyroid Carcinomas

4.1. Medullary Thyroid Carcinoma (MTC)

4.1.1. Introduction. Epidemiology
4.1.2. Classification. Anatomopathological Features
4.1.3. Clinical Manifestations
4.1.4. Genetic Studies

4.2. MTC: Initial Staging Dynamic Risk Staging
4.3. Diagnosis of CMT

4.3.1. Laboratory Tests
4.3.2. Imaging Tests
4.3.3. FNA with Ultrasound Monitoring

4.4. MTC: Surgical Treatment

4.4.1. Surgical Scope
4.4.2. Surgical Treatment for Relapse
4.4.3. Surgical Treatment for Metastasis

4.5. MTC: Radiotherapy Radionuclide Therapy
4.6. MTC: Advanced Unresectable Disease Treatment

4.6.1. Tyrosine Kinase Inhibitors
4.6.2. Other Treatments

4.7. MTC: Monitoring and Prognosis
4.8. Poorly Differentiated Thyroid Carcinoma: Anaplastic Carcinoma
4.9. Thyroid Lymphoma and Other Rare Thyroid Malignancies: Metastases of Other Tumors

Module 5. Adrenal Cortex Tumors

5.1. Adrenal Incidentaloma: Diagnostic Approach
5.2. ACTH Independent Cushing's Syndrome Caused by Adrenal Adenoma
5.3. Primary Hyperaldosteronism: Cohn's Disease
5.4. Adrenocortical Carcinoma (ACC)

5.4.1. Introduction
5.4.2. Medical History and Examination

5.5. ACC: Genetic Aspects Laboratory Data Hormone Secretion
5.6. ACC: Imaging Tests Ultrasound. CT, MRI, PET-CT
5.7. ACC: Pathological Anatomy. Staging. Prognostic Factors
5.8. Surgical Treatment

5.8.1. Surgical Treatment for Primary Tumors
5.8.2. Surgery and Other Local Treatments for Advanced Disease

5.9. Adjuvant: Radiotherapy Relapse Treatment
5.10. Treating Advanced Stages of the Disease

Module 6. Pheochromocytomas and Paragangliomas

6.1. Introduction

6.1.1. Anatomy Recap
6.1.2. Epidemiology

6.2. Molecular Basis: Genotype-Phenotype Correlation
6.3. Clinical Manifestations: Ways It Presents Itself
6.4. Laboratory Data
6.5. Imaging Tests
6.6. Surgical Treatment

6.6.1. Adrenergic Block
6.6.2. Surgery for Pheochromocytomas and Paragangliomas: Embolization

6.7. Radionuclide Therapy: Radiotherapy
6.8. Treating Advanced Stages of the Disease
6.9. Prognosis and Monitoring

6.9.1. Different Mutation Carrier Monitoring
6.9.2. Long-Term Monitoring
6.9.3. Prognosis

6.10. Importance of Tumor Committees and Patient Associations

6.10.1. Multidisciplinary Approach
6.10.2. Role of Patient Associations

Module 7. Multiple Endocrine Neoplasm Syndromes

7.1. Multiple Endocrine Neoplasia Type I (MEN I): Genetics

7.1.1. MEN I Genetics
7.1.2. When to Perform a Genetic Study to Rule Out Mutation in the Menin Gene
7.1.3. Genetic Counseling for MEN I: Preimplantational Diagnosis

7.2. Clinical Manifestations of the Syndrome: Ways MEN I Presents Itself
7.3. Laboratory Tests at Initial Evaluation and Subsequent Monitoring
7.4. MEN I. Imaging Tests at Initial Evaluation and Subsequent Monitoring
7.5. MEN I. Primary Hyperparathyroidism (PHPT) Treatment: Relapse Management
7.6. MEN I. Pancreatic Neuroendocrine Tumors: Surgical Indications
7.7. Managing of Other Tumors

7.7.1. Neuroendocrine Tumors (NETs) in Atypical Locations: Bronchial and Thymic NETs
7.7.2. Screening, Monitoring and Treatment for Other Neoplasms

7.8. Multiple Endocrine Neoplasm Type II (MEN II): MEN II Genetics

7.8.1. RET Oncogene
7.8.2. Genotype-Phenotype Correlation
7.8.3. Less Common Mutations

7.9. MEN II: Medullary Carcinoma

7.9.1. Evaluation and Monitoring after Knowing the Carrier's Condition
7.9.2. Prophylactic Thyroidectomy

7.10. MEN II: Primary Pheochromocytoma and Hyperparathyroidism

7.10.1. Evaluation and Monitoring after Knowing the Carrier's Condition
7.10.2. Indications for Hyperparathyroidism Treatment in MEN II Patients

7.11. MEN II: Other MEN II Manifestations
7.12. Others Multiple Endocrine Neoplasm Syndromes

Module 8. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

8.1. Gastroenteropancreatic Neuroendocrine Tumors

8.1.1. Concept
8.1.2. Epidemiology

8.2. Moleculary and Cellular Basis
8.3. Pathological Anatomy

8.3.1. Classification Systems

8.4. Lung and Thymus NETs
8.5. Gastric NETs
8.6. Intestinal NETs: Appendix NET
8.7. Non-Functioning Pancreatic NETs
8.8. Gastrinoma
8.9. Insulinoma
8.10. Gucagonoma, Somatostatinoma, Vipoma: Other Functioning Tumors

Module 9. GEP-NET: Anatomical and Functional Diagnosis Treating Locoregional Disease

9.1. Carcinoid Syndrome: Carcinoid Cardiopathy
9.2. ACTH and Other Hormone Ectopic Secretion Syndromes
9.3. GEP-NET Diagnosis and Monitoring: Biological Markers

9.3.1. Usefulness in Diagnosis and Monitoring

9.4. GEP-NET Diagnosis and Monitoring: Endoscopy and Echoendoscopy-Guided Fine Needle Aspiration Puncture (FNA) in the Diagnosis and Monitoring of GEP-NET
9.5. GEP-NET Diagnosis and Monitoring: Imaging Tests I

9.5.1. Ultrasound, Computerized Tomography, Magnetic Resonance Imaging
9.5.2. Treatment Response Criteria (RECIST, Choi, and Others)

9.6. GEP-NET Diagnosis and Monitoring: Imaging Tests II Nuclear Medicine in the Diagnosis and Monitoring of GEP-NETs
9.7. Surgical Treatment for Pulmonary NET
9.8. Surgical Treatment for Gastric NET
9.9. Surgical Treatment for Intestinal NET
9.10. Surgical Treatment for Pancreatic NET

9.10.1. Treatment for Incidentally Discovered Non-Functioning Pancreatic NETs: Surgery / Monitoring

9.11. Surgical Treatment for G3 Tumors: Surgical Treatment for MINEN

Module 10. Gastroenteropancreatic Neuroendocrine Tumors: Treating Advanced Stages of the Disease

10.1. Surgical Treatment in Advanced Stages of the Disease

10.1.1. Surgical Treatment Indication for Primary Tumors
10.1.2. Surgical Treatment for Liver and Other Metastases

10.2. Locoregional Treatments

10.2.1. Embolization
10.2.2. Radiofrequency
10.2.3. Other Locoregional Treatments

10.3. Biological Treatments: Somatostatin Analogues and Others
10.4. Chemotherapy and Targeted Therapies: Role of Immunotherapy
10.5. Theragnosis: Radionuclide Therapy
10.6. Treatment Sequencing
10.7. Nutritional Management for GEP-NET Patients
10.8. Importance of Tumor Committees and Patient Associations

10.8.1. Multidisciplinary Approach
10.8.2. Role of Patient Associations: NET Spain

The first phase of this Hybrid professional master’s degree will be based on a 100% online platform with multimedia resources of great didactic value for the theoretical mastery of its contents”